DOCSLIB.ORG

Sup Table 1.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Supplemental Table 1. Full annotation of all differentially expressed genes between IS tissue of Day 7.5 pregnant Il15+/+ and Il15-/- mice as determined by microarray analysis. log2(Fold‐ Chromosome change Probe Symbol Description Chromosome GenBank Gene Cytoband UniGene PubMed Gene Ontology Pathway P.Adjusted Location Il15+/+/Il1 5‐/‐) XM_901690, XM_903949, XM_922038 molecular_function XM_901690, 1110038B RIKEN cDNA ‐35087182, ‐ 1990400 17 XM_903949, 68763 17 17 B1 Mm.28895 14 ‐0.593333 0.00134 12Rik 1110038B12 gene 35087182 XM_922038 XM_901690, XM_903949, XM_922038 cellular_component biological_process molecular_function cellular_component 1500015O RIKEN cDNA 3130368 1 43787446 NM_024283 78896 1 1 C1 Mm.50109 14 extracellular region ‐0.753333 0.001134 10Rik 1500015O10 gene biological_process cytoplasmic vesicle molecular_function cellular_component 2010011I RIKEN cDNA 1.03E+08 2 172171076 67017 2 2 H3 Mm.30013 12 biological_process WT Only WT Only 20Rik 2010011I20 gene membrane integral to membrane molecular_function cellular_component RIKEN cDNA nucleus 2500003 1.07E+08 2500003M10 3 ‐90302879 66511 3 3 F2 Mm.154136 17 ‐0.543333 0.000797 M10Rik gene transcription biological_process regulation of transcription molecular_function 2510016G RIKEN cDNA 1.02E+08 7 72438 7 Mm.394279 7 cellular_component ‐0.576667 0.003076 02Rik 2510016G02 gene biological_process molecular_function 2900046B RIKEN cDNA 2630725 9 74327 9 Mm.5264 7 cellular_component 0.613333 0.00033 09Rik 2900046B09 gene biological_process molecular_function 2900046B RIKEN cDNA 4810324 9 74327 9 Mm.5264 7 cellular_component 0.623333 0.000638 09Rik 2900046B09 gene biological_process molecular_function 5031414D RIKEN cDNA 4850494 14 75415833 NM_198642 271221 14 14 D3 Mm.320280 8 cellular_component ‐0.666667 0.004576 18Rik 5031414D18 gene biological_process molecular_function 6330403K RIKEN cDNA 2060504 11 ‐70845442 NM_134022 103712 11 11 B4 Mm.27768 13 cellular_component WT Only WT Only 07Rik 6330403K07 gene biological_process molecular_function RIKEN cDNA 6720422 1.05E+08 6720422M22 3 99946 Mm.440672 7 cellular_component KO Only KO Only M22Rik gene biological_process molecular_function 9130230L RIKEN cDNA Mm.436542 1450315 5 ‐66379166 XR_035361 231253 5 5 C3.1 9 cellular_component 0.78 0.008423 23Rik 9130230L23 gene Mm.478504 biological_process molecular_function 9130230L RIKEN cDNA Mm.436542 2190452 5 ‐66379166 XR_035361 231253 5 5 C3.1 9 cellular_component 1.17667 0.002484 23Rik 9130230L23 gene Mm.478504 biological_process molecular_function 9330182O RIKEN cDNA 1.02E+08 15 328531 15 15 B3.1 Mm.60703 7 cellular_component 0.643333 0.007724 14Rik 9330182O14 gene biological_process molecular_function A030010E RIKEN cDNA 1.06E+08 9 320039 9 Mm.208296 7 cellular_component 0.696667 0.003566 16Rik A030010E16 gene biological_process molecular_function A430005L RIKEN cDNA 4200273 4 153331345 NM_175287 97159 4 4 E2 Mm.7066 14 cellular_component ‐0.543333 0.005176 14Rik A430005L14 gene biological_process nucleotide binding ATP binding lysosome lysosome endosome late endosome Golgi apparatus Golgi apparatus ATP‐binding transport cassette, sub‐ ABC 1660110 Abca5 11 ‐110130682 NM_147219 217265 11 11 E1 Mm.41942 14 WT only WT Only family A (ABC1), transporters negative regulation of macrophage derived member 5 foam cell differentiation membrane integral to membrane ATPase activity nucleoside‐triphosphatase activity cholesterol efflux high‐density lipoprotein particle remodeling reverse cholesterol transport molecular_function NM_016703*, carboxylesterase activity NM_021304, NR_003522 cellular_component abhydrolase NM_016703*, 31252438, 6220685 Abhd1 domain 5 NM_021304, 57742 5 5 B1 Mm.389615 13 biological_process ‐0.656667 0.004949 31252478 containing 1 NR_003522 NM_016703*, membrane NM_021304, NR_003522 integral to membrane hydrolase activity carboxylesterase activity response to wounding abhydrolase membrane 4850504 Abhd2 domain 7 86418151 NM_018811 54608 7 7 D2 Mm.365490 14 0.596667 0.000561 containing 2 integral to membrane hydrolase activity negative regulation of cell migration Fatty acid molecular_function metabolism Valine, leucine and mitochondrion isoleucine degradation acetyl‐Coenzyme Biosynthesis 6100750 Acaa1b A acyltransferase 9 ‐119057160 NM_146230 235674 9 9 F3 Mm.379402 13 of ‐0.503333 0.001556 biological_process 1B unsaturated fatty acids Metabolic pathways PPAR signaling pathway Peroxisome Acap1 molecular_function phospholipase C activity signal transducer activity cellular_component lipid metabolic process signal transduction ArfGAP with NM_153788, ARF GTPase activator activity coiled‐coil, XR_032069 2120093 0.65 0.004127 ankyrin repeat NM_153788, biological_process and PH domains 1 XR_032069 zinc ion binding lipid catabolic process hydrolase activity intracellular signaling pathway regulation of ARF GTPase activity metal ion binding Purine in utero embryonic development metabolism Metabolic trophectodermal cell differentiation pathways Primary purine nucleoside binding immunodefi ciency liver development placenta development germinal center B cell differentiation positive regulation of germinal center formation negative regulation of leukocyte migration negative regulation of leukocyte migration negative regulation of mature B cell apoptosis adenosine deaminase activity adenosine deaminase activity adenosine deaminase activity adenosine deaminase activity extracellular space cytoplasm cytoplasm plasma membrane adenosine catabolic process adenosine catabolic process adenosine catabolic process deoxyadenosine catabolic process deoxyadenosine catabolic process cell adhesion nucleotide metabolic process purine ribonucleoside monophosphate biosynthetic process positive regulation of heart rate membrane hydrolase activity deaminase activity cell junction adenosine 2 94.0 cM 2 3130075 Ada 2 ‐163552319 NM_007398 11486 Mm.388 117 1.41667 0.017497 deaminase H3 lung development positive regulation of B cell proliferation dendrite cytoplasm positive regulation of T cell differentiation in the thymus neuronal cell body negative regulation of apoptosis regulation of T cell differentiation positive regulation of T cell differentiation positive regulation of smooth muscle contraction dATP catabolic process dATP catabolic process adenosine metabolic process hypoxanthine biosynthetic process inosine biosynthetic process inosine biosynthetic process inosine biosynthetic process xanthine biosynthetic process positive regulation of alpha‐beta T cell differentiation metal ion binding lung alveolus development Peyer's patch development embryonic digestive tract development negative regulation of inflammatory response negative regulation of inflammatory response positive regulation of calcium‐mediated signaling positive regulation of T cell receptor signaling pathway positive regulation of T cell activation negative regulation of penile erection negative regulation of thymocyte apoptosis negative regulation of mucus secretion negative regulation of mucus secretion metalloendopeptidase activity extracellular region proteinaceous extracellular matrix proteolysis integrin‐mediated signaling pathway a disintegrin‐like and metabolic process NM_011782, metallopeptidase XM_001480027 5890592 Adamts5 (reprolysin type) peptidase activity 0.836667 0.002307 NM_011782, with XM_001480027 thrombospondin metallopeptidase activity type 1 motif, 5 metallopeptidase activity zinc ion binding hydrolase activity extracellular matrix metal ion binding adenosine receptor activity, G‐protein coupled adenosine receptor activity, G‐protein coupled positive regulation of chronic inflammatory response to non‐antigenic stimulus signal transducer activity receptor activity G‐protein coupled receptor activity G‐protein coupled receptor activity plasma membrane plasma membrane plasma membrane signal transduction G‐protein coupled receptor protein signaling pathway activation of adenylate cyclase activity by G‐ protein signaling pathway positive regulation of cell proliferation negative regulation of cell proliferation cell surface positive regulation vascular endothelial growth factor production NM_007413, positive regulation of norepinephrine adenosine A2b XM_001473907 secretion 6860253 Adora2b ‐0.546667 0.002398 receptor NM_007413, XM_001473907 positive regulation of steroid biosynthetic process membrane integral to membrane positive regulation of cAMP biosynthetic process positive regulation of cAMP biosynthetic process positive regulation of cGMP biosynthetic process positive regulation of guanylate cyclase activity cellular response to extracellular stimulus positive regulation of chemokine production positive regulation of interleukin‐6 production negative regulation of collagen biosynthetic process positive regulation of catecholamine secretion positive regulation of mast cell degranulation regulation of angiogenesis positive regulation of vasodilation relaxation of vascular smooth muscle nucleotide binding protein kinase activity protein serine/threonine kinase activity G‐protein coupled receptor kinase activity G‐protein coupled receptor kinase activity signal transducer activity ATP binding nucleus protein amino acid phosphorylation adrenergic Olfactory ‐113389583, ‐ 1.03E+08 Adrbk2 receptor kinase, 5 NM_001035531 320129 5 60.0 cM 5 F Mm.285619 30 protein amino acid phosphorylation transductio 0.553333 0.001944 113339497 beta 2 n signal transduction kinase activity phosphorylation phosphorylation transferase activity axon dendritic spine dendritic shaft synapse beta‐adrenergic receptor kinase activity
Recommended publications
  • DDAH I (C-19): Sc-26068

    DDAH I (C-19): Sc-26068

    SANTA CRUZ BIOTECHNOLOGY, INC. DDAH I (C-19): sc-26068 The Power to Question BACKGROUND APPLICATIONS DDAH, a dimethylarginine dimethylaminohydrolase, hydrolyzes dimethyl DDAH I (C-19) is recommended for detection of DDAH I of mouse, rat and arginine (ADMA) and monomethyl arginine (MMA), both inhibitors of nitric human origin by Western Blotting (starting dilution 1:200, dilution range oxide synthases, and may be involved in in vivo modulation of nitric oxide 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution production. Impairment of DDAH causes ADMA accumulation and a reduc- range 1:50-1:500). tion in cGMP generation. DDAH II, the predominant DDAH isoform in endothelial cells, facilitates the induction of nitric oxide synthesis by all- RECOMMENDED SECONDARY REAGENTS trans-Retinoic acid (atRA). DDAH proteins are highly expressed in colon, kid- To ensure optimal results, the following support (secondary) reagents are ney, stomach and liver tissues. recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti- REFERENCES goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ 1. Nakagomi, S., et al. 1999. Dimethylarginine dimethylaminohydrolase Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: (DDAH) as a nerve-injury-associated molecule: mRNA localization in the sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluores- rat brain and its coincident up-regulation with neuronal NO synthase cence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) (nNOS) in axotomized motoneurons. Eur. J.
  • Enzymatic Encoding Methods for Efficient Synthesis Of

    Enzymatic Encoding Methods for Efficient Synthesis Of

    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
  • Generated by SRI International Pathway Tools Version 25.0, Authors S

    Generated by SRI International Pathway Tools Version 25.0, Authors S

    An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_000238675-HmpCyc: Bacillus smithii 7_3_47FAA Cellular Overview Connections between pathways are omitted for legibility.
  • Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals

    Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals

    Journal of the American Heart Association ORIGINAL RESEARCH Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals Joonatan Palmu , MD; Aaro Salosensaari , MSc; Aki S. Havulinna , DSc (Tech); Susan Cheng , MD, MPH; Michael Inouye, PhD; Mohit Jain, MD, PhD; Rodolfo A. Salido , BSc; Karenina Sanders , BSc; Caitriona Brennan, BSc; Gregory C. Humphrey, BSc; Jon G. Sanders , PhD; Erkki Vartiainen , MD, PhD; Tiina Laatikainen , MD, PhD; Pekka Jousilahti, MD, PhD; Veikko Salomaa , MD, PhD; Rob Knight , PhD; Leo Lahti , DSc (Tech); Teemu J. Niiranen , MD, PhD BACKGROUND: Several small-scale animal studies have suggested that gut microbiota and blood pressure (BP) are linked. However, results from human studies remain scarce and conflicting. We wanted to elucidate the multivariable-adjusted as- sociation between gut metagenome and BP in a large, representative, well-phenotyped population sample. We performed a focused analysis to examine the previously reported inverse associations between sodium intake and Lactobacillus abun- dance and between Lactobacillus abundance and BP. METHODS AND RESULTS: We studied a population sample of 6953 Finns aged 25 to 74 years (mean age, 49.2±12.9 years; 54.9% women). The participants underwent a health examination, which included BP measurement, stool collection, and 24-hour urine sampling (N=829). Gut microbiota was analyzed using shallow shotgun metagenome sequencing. In age- and sex-adjusted models, the α (within-sample) and β (between-sample) diversities of taxonomic composition were strongly re- lated to BP indexes (P<0.001 for most). In multivariable-adjusted models, β diversity was only associated with diastolic BP (P=0.032).
  • Links Among Neuronal Nitric Oxide Synthase, Oxidative Stress, and Asymmetric Dimethylarginine (Adma)

    Links Among Neuronal Nitric Oxide Synthase, Oxidative Stress, and Asymmetric Dimethylarginine (Adma)

    NITRIC OXIDE DEFICIENCY IN CHRONIC KIDNEY DISEASE: LINKS AMONG NEURONAL NITRIC OXIDE SYNTHASE, OXIDATIVE STRESS, AND ASYMMETRIC DIMETHYLARGININE (ADMA) By YOU-LIN TAIN A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2007 1 © 2007 You-Lin Tain 2 This dissertation is dedication to my family for their constant love 3 ACKNOWLEDGMENTS This dissertation would not have been possible without the support of many people. Many thanks go to my adviser: Dr. Chris Baylis gave me the chance to work on many projects and also gave me numerous valuable comments for my manuscripts. I would like to thank my committee members for their guidance and valuable comments: Dr. Richard Johnson, Dr. Mohan Raizada, and Dr. Mark Segal. I thanks also go to the Chang Gung Memorial Hospital for awarding me a fellowship, providing me with the financial means to complete this dissertation. I am grateful to many persons who shared their technical assistance and experience, especially Dr. Verlander and Dr. Chang (University of Florida), Dr. Muller and Dr. Szabo (Semmelweis University, Hungary), Dr. Griendling and Dr. Dikalova (Emory University), and Dr. Merchant and Dr. Klein (University of Louisville). Next, I would like to thank all of the members of Dr. Baylis lab, both past and present, with whom I have been fortunate enough to work: Dr. Aaron Erdely, Gerry Freshour, Kevin Engels, Lennie Samsell, Dr. Sarah Knight, Dr. Cheryl Smith, Dr. Jenny Sasser, Harold Snellen, Bruce Cunningham, Gin-Fu Chen, and Natasha Moningka.
  • Circuits Regulating Superoxide and Nitric Oxide

    Circuits Regulating Superoxide and Nitric Oxide

    antioxidants Article Circuits Regulating Superoxide and Nitric Oxide Production and Neutralization in Different Cell Types: Expression of Participating Genes and Changes Induced by Ionizing Radiation 1,2, 1,2, 1 1,2, Patryk Bil y, Sylwia Ciesielska y, Roman Jaksik and Joanna Rzeszowska-Wolny * 1 Department of Systems Biology and Engineering, Faculty of Automatic Control, Electronics and Computer Science, Silesian University of Technology, 44-100 Gliwice, Poland; [email protected] (P.B.); [email protected] (S.C.); [email protected] (R.J.) 2 Biotechnology Centre, Silesian University of Technology, 44-100 Gliwice, Poland * Correspondence: [email protected] These authors contributed equally. y Received: 30 June 2020; Accepted: 29 July 2020; Published: 3 August 2020 Abstract: Superoxide radicals, together with nitric oxide (NO), determine the oxidative status of cells, which use different pathways to control their levels in response to stressing conditions. Using gene expression data available in the Cancer Cell Line Encyclopedia and microarray results, we compared the expression of genes engaged in pathways controlling reactive oxygen species and NO production, neutralization, and changes in response to the exposure of cells to ionizing radiation (IR) in human cancer cell lines originating from different tissues. The expression of NADPH oxidases and NO synthases that participate in superoxide radical and NO production was low in all cell types. Superoxide dismutase, glutathione peroxidase, thioredoxin, and peroxiredoxins participating in radical neutralization showed high expression in nearly all cell types. Some enzymes that may indirectly influence superoxide radical and NO levels showed tissue-specific expression and differences in response to IR.
  • Transcriptional Analysis of Sodium Valproate in a Serotonergic Cell Line Reveals Gene Regulation Through Both HDAC Inhibition-Dependent and Independent Mechanisms

    Transcriptional Analysis of Sodium Valproate in a Serotonergic Cell Line Reveals Gene Regulation Through Both HDAC Inhibition-Dependent and Independent Mechanisms

    bioRxiv preprint doi: https://doi.org/10.1101/837732; this version posted November 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms Priyanka Sinha1,2, Simone Cree1,2, Allison L. Miller1,2, John F. Pearson1,2,3, Martin A. Kennedy1,2. 1Gene Structure and Function Laboratory, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. 2Carney Centre for Pharmacogenomics, University of Otago, Christchurch, New Zealand. 3Biostatistics and Computational Biology Unit, University of Otago, Christchurch, New Zealand. Correspondence to: Prof. M. A. Kennedy Department of Pathology and Biomedical Science University of Otago, Christchurch Christchurch, New Zealand Email: [email protected] Keywords: RNA-Seq, NanoString, lithium, valproate, HDAC inhibitor, mood stabilizer 1 bioRxiv preprint doi: https://doi.org/10.1101/837732; this version posted November 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Sodium valproate (VPA) is a histone deacetylase (HDAC) inhibitor, widely prescribed in the treatment of bipolar disorder, and yet the precise modes of therapeutic action for this drug are not fully understood.
  • Gene Transfer As a Potential Treatment for Tetralujdrobiopterin Deficient States

    Gene Transfer As a Potential Treatment for Tetralujdrobiopterin Deficient States

    Gene Transfer as a Potential Treatment for Tetralujdrobiopterin Deficient States Rickard F oxton Division of Neurochemistry Department of Molecular Neuroscience Institute of Neurology University College London Submitted November 2006 Funded by Brain Research Trust Thesis submitted for the degree of Doctor of Philosophy, University of London. I, Richard Hartas Foxton, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.' 1 UMI Number: U592813 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U592813 Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Tetrahydrobiopterin (BH4) is an essential cofactor for dopamine (DA), noradrenaline (NA), serotonin and nitric oxide (NO) synthesis in the brain. Inborn errors of BH4 metabolism including GTP cyclohydrolase 1 (GTP-CH) deficiency are debilitating diseases in which BH4, DA, 5-HT and NO metabolism are impaired. Current treatment for these disorders is typically monoamine replacement +/- BH4. Whilst correction of the primary defect is the ideal, BH4 treatment is problematic as it is expensive and inefficacious.
  • Copyright by Yun Wang 2010

    Copyright by Yun Wang 2010

    Copyright by Yun Wang 2010 The Dissertation Committee for Yun Wang Certifies that this is the approved version of the following dissertation: Controlling Nitric Oxide (NO) Overproduction: Nω, Nω- Dimethylarginine Dimethylaminohydrolase (DDAH) as a Novel Drug Target Committee: Walter L. Fast, Supervisor Christian P. Whitman Jon D. Robertus George Georgiou Sean M. Kerwin Controlling Nitric Oxide (NO) Overproduction: Nω, Nω- Dimethylarginine Dimethylaminohydrolase (DDAH) as a Novel Drug Target by Yun Wang, B.S.; M.S. Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin August, 2010 Dedication To all people who have given me generous help when I am in Austin, including professors, colleagues and friends. To my beloved parents in P.R.China, who always motivate me to pursue my dream. Acknowledgements First and foremost, I would like to thank my supervisor, Dr. Walt Fast, for his generous support and for giving me an opportunity to work in his lab four years ago at the University of Texas at Austin. Walt gives me lots of freedom to explore scientific problems and provides a wonderful working environment along with my lovely colleagues. He always gives me useful directions when I meet difficulties. I appreciate every scientific conversation with him. They were especially important to me during the beginning of my Ph.D. study. I wouldn’t have accomplished as much as today without his help. In addition, I’d like to thank colleagues in Fast lab for their generous help during these years.
  • (10) Patent No.: US 8119385 B2

    (10) Patent No.: US 8119385 B2

    US008119385B2 (12) United States Patent (10) Patent No.: US 8,119,385 B2 Mathur et al. (45) Date of Patent: Feb. 21, 2012 (54) NUCLEICACIDS AND PROTEINS AND (52) U.S. Cl. ........................................ 435/212:530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search ........................ None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Houston, TX (US) OTHER PUBLICATIONS c Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (*) Notice: Subject to any disclaimer, the term of this bor New York, 2001, pp. 382-393.* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 689 days. Isolates of Pseudomonas aeruginosa” J. Bacteriol. (2003) 185: 1316 1325. (21) Appl. No.: 11/817,403 Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. 2002. (22) PCT Fled: Mar. 3, 2006 Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (86). PCT No.: PCT/US2OO6/OOT642 toxicology” Toxicol. Lett. (2000) 1.12: 365-370. S371 (c)(1), * cited by examiner (2), (4) Date: May 7, 2008 Primary Examiner — James Martinell (87) PCT Pub. No.: WO2006/096527 (74) Attorney, Agent, or Firm — Kalim S. Fuzail PCT Pub. Date: Sep. 14, 2006 (57) ABSTRACT (65) Prior Publication Data The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides US 201O/OO11456A1 Jan. 14, 2010 encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides.
  • The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose

    The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose

    Page 1 of 230 Diabetes Title: The microbiota-produced N-formyl peptide fMLF promotes obesity-induced glucose intolerance Joshua Wollam1, Matthew Riopel1, Yong-Jiang Xu1,2, Andrew M. F. Johnson1, Jachelle M. Ofrecio1, Wei Ying1, Dalila El Ouarrat1, Luisa S. Chan3, Andrew W. Han3, Nadir A. Mahmood3, Caitlin N. Ryan3, Yun Sok Lee1, Jeramie D. Watrous1,2, Mahendra D. Chordia4, Dongfeng Pan4, Mohit Jain1,2, Jerrold M. Olefsky1 * Affiliations: 1 Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 2 Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 3 Second Genome, Inc., South San Francisco, California, USA. 4 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. * Correspondence to: 858-534-2230, [email protected] Word Count: 4749 Figures: 6 Supplemental Figures: 11 Supplemental Tables: 5 1 Diabetes Publish Ahead of Print, published online April 22, 2019 Diabetes Page 2 of 230 ABSTRACT The composition of the gastrointestinal (GI) microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine (fMLF), are elevated in high fat diet (HFD)- induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon- like peptide-1 (GLP-1). Obese Fpr1-knockout (Fpr1-KO) mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota.
  • SET-Induced Calcium Signaling and MAPK/ERK Pathway Activation Mediate Dendritic Cell-Like Differentiation of U937 Cells

    SET-Induced Calcium Signaling and MAPK/ERK Pathway Activation Mediate Dendritic Cell-Like Differentiation of U937 Cells

    Leukemia (2005) 19, 1439–1445 & 2005 Nature Publishing Group All rights reserved 0887-6924/05 $30.00 www.nature.com/leu SET-induced calcium signaling and MAPK/ERK pathway activation mediate dendritic cell-like differentiation of U937 cells A Kandilci1 and GC Grosveld1 1Department of Genetics and Tumor Cell Biology, Mail Stop 331, St Jude Children’s Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA Human SET, a target of chromosomal translocation in human G1/S transition by allowing cyclin E–CDK2 activity in the leukemia encodes a highly conserved, ubiquitously expressed, presence of p21.11 Second, SET interacts with cyclin B–CDK1.19 nuclear phosphoprotein. SET mediates many functions includ- ing chromatin remodeling, transcription, apoptosis and cell Overexpression of SET inhibits cyclin B-CDK1 activity, which in cycle control. We report that overexpression of SET directs turn, blocks the G2/M transition; this finding suggests a negative 13 differentiation of the human promonocytic cell line U937 along regulatory role for SET in G2/M transition. Overexpression of the dendritic cell (DC) pathway, as cells display typical cell division autoantigen-1 (CDA1), another member of the morphologic changes associated with DC fate and express NAP/SET family, inhibits proliferation and decreases bromo- the DC surface markers CD11b and CD86. Differentiation occurs deoxyuridine uptake in HeLa cells.20 Acidic and basic domains via a calcium-dependent mechanism involving the CaMKII and 20 MAPK/ERK pathways. Similar responses are elicited by inter- of CDA1 show 40% identity and 68% similarity to SET. feron-c (IFN-c) treatment with the distinction that IFN-c signaling We have recently shown that overexpression of SET in the activates the DNA-binding activity of STAT1 whereas SET human promonocytic cell line U937 causes G0/G1 arrest and overexpression does not.